Purchase Link:
http://www.research-store.com/fiercebiotech/Product/pipeline_and_commercial_insight_supportive_care_in_oncology_innovation_and_market_growth_opportunities_in_bone_metastases_and_emerging_supportive_care_challenges?productid=DMHC2557
Introduction
Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies The supportive care market is potentially vast, therefore this report focuses on the cytopenias (anemia, neutropenia and thrombocytopenia), chemotherapy-induced nausea and vomiting, and bone metastases.
Scope of this research
- In-depth analysis of the current and future oncology supportive care market across the US, 5EU and Japan, plus a rest of world snapshot
- Oncology supportive care therapy sales forecasts for brands, generics, biosimilars and late-phase pipeline candidates from 2008 to 2018
- Assessment of the leading supportive care brands and drug classes to identify key success factors within this sector
- Examination of the oncology supportive care pipeline with in-depth clinical and commercial profiles of Phase III candidates
Research and analysis highlights
The supportive care market will shrink at a CAGR of -0.6%, with sales dropping from $10.3 billion in 2008 to $9.3 billion in 2018. This is due to the effect of patent expiry and generic/biosimilar erosion, as well ongoing restrictions on use of erythropoietins. Pipeline launches during this time will be insufficient to offset this sales decline.
In 2008, Neulasta (pegfilgrastim; Amgen/Kyowa Kirin) and Neupogen (filgrastim; Amgen/Kyowa Kirin) were the leading supportive care brands, with sales well over $1 billion. Despite facing patent expiry and the increasing threat of biosimilar entry, Neulasta and Neupogen will remain in the top three in 2018, along with Prolia (denosumab; Amgen).
Growth in the market will come mainly from expanded use of current products into new indications and markets. The current pipeline is relatively sparse, however, the greatest breakthrough will occur via Prolia (denosumab; Amgen) for bone metastases. The greatest future growth will come from development in emerging supportive care challenges.
Key reasons to purchase this research
- Quantify the performance of each of the marketed oncology supportive care brands in the seven major markets over the period 2008 to 2018
- Acquire a detailed account of oncology supportive care brand dynamics and the events that drive and limit their market growth
- Benchmark the oncology supportive care brands against their generics/biosimilars and align their 7MM performance with a rest of world snapshot
Teaser:
Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies The supportive care market is potentially vast, therefore this report focuses on the cytopenias (anemia, neutropenia and thrombocytopenia), chemotherapy-induced nausea and vomiting, and bone metastases.
